Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24931121 | 0.89 | ALDH1A1 (0.45) | CYP3A4SIGMAR1IDO1ADORA3ADORA2A | |
| SCHEMBL20140432 | 0.78 | CKS1B (0.45) | CYP3A4SIGMAR1IDO1DRD2AKT1 | |
| SCHEMBL20140105 | 0.77 | CKS1B (0.44) | CYP3A4SIGMAR1IDO1DRD2CKS1B | |
| SCHEMBL18187542 | 0.76 | IDO1 (0.43) | SIGMAR1IDO1DRD2AKT1ADORA3 | |
| SCHEMBL30239072 | 0.76 | IDO1 (0.44) | SIGMAR1IDO1DRD2AKT1ADORA3 | |
| SCHEMBL9357566 | 0.76 | PIM1 (0.46) | SIGMAR1IDO1AGTR1DRD2AKT1 | |
| SCHEMBL24484299 | 0.73 | AKT1 (0.39) | CYP3A4SIGMAR1IDO1DRD2AKT1 | |
| SCHEMBL1537644 | 0.72 | CYP3A4 (0.60) | CYP3A4SIGMAR1IDO1 | |
| SCHEMBL31357676 | 0.72 | BCHE (0.47) | DRD2 | |
| SCHEMBL31357702 | 0.72 | CNR2 (0.45) | CYP3A4DRD2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | CYP3A4 4066/4885SIGMAR1 4213/4885IDO1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.